FDA: AZ/Ardea Gout Drug Modest Efficacy, Safety Concerns
This article was originally published in Scrip
An experimental gout drug from AstraZeneca plc unit Ardea Biosciences Inc., known as lesinurad, demonstrated only modest efficacy in clinical trials and has some concerning adverse cardiovascular (CV) and renal-related effects, FDA drug reviewers said on Oct. 21.
You may also be interested in...
What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December, but not yet launched.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.